NewGenIvf Group Limited Class A Ordinary Shares (NIVF)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $369,510
Last updated: Nov 17, 2026 at 11:03 AM ET
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Financials: Revenue, Profit and Cash Flow
NewGenIvf Group Limited Class A Ordinary Shares reported revenue of $4.73M for the fiscal year ended Dec 31, 2025, down 13.0% from the year before. That year, net income was $9.88M with a net margin of 209.0%, operating cash flow was -$10.93M and free cash flow was -$16.68M. The quarter ended Sep 30, 2026 had revenue of $1.92B and net income of -$8.04B.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.73M | -13.0% | 20.2% | -226.9% | 209.0% |
| Dec 2024 | $5.43M | +5.8% | 33.6% | -21.4% | -9.7% |
| Dec 2023 | $5.14M | -13.6% | 32.7% | -49.1% | -13.5% |
| Dec 2022 | $5.94M | +44.3% | 25.9% | 6.7% | 7.7% |
| Dec 2021 | $4.12M | N/A | 24.9% | 4.8% | 0.0% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $4.73M | $5.43M | $5.14M | $5.94M | $4.12M |
| Cost of revenue | $3.77M | $3.61M | $3.45M | $4.41M | $3.09M |
| Gross profit | $955.85K | $1.83M | $1.68M | $1.54M | $1.02M |
| Operating income | -$10.73M | -$1.16M | -$2.52M | $398.70K | $198.76K |
| Net income | $9.88M | -$525.00K | -$690.85K | $458.67K | -$533 |
| EBITDA | $10.84M | $24.26K | -$2.52M | $725.69K | $587.01K |
Quarterly
| Line item | Sep 2026 | Dec 2025 | Sep 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.92B | $1.42M | $1.28M | $1.27M | $1.27M | $1.47M | $1.52M | N/A | N/A | N/A | N/A | N/A |
| Gross profit | $464.49M | $524.02K | $118.02K | $539.13K | $539.13K | $648.83K | $196.82K | N/A | N/A | N/A | N/A | N/A |
| Operating income | -$3.55B | -$4.97M | -$2.51M | -$1.09M | -$1.09M | $216.31K | $196.82K | -$1.27M | -$377.72K | -$367.00K | -$510.55K | -$115.64K |
| Net income | -$8.04B | -$7.67M | $16.82M | -$108.00K | -$108.24K | -$19.86K | $335.63K | -$955.49K | $127.02K | $85.50K | $52.12K | $474.36K |
Balance Sheet
As of Dec 2025, total debt of $4.59M exceeded cash and equivalents by $3.83M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total assets | $32.72M | $3.58M | $21.32M | $2.90M | $1.41M |
| Current assets | $7.38M | $3.17M | $50.78K | $2.40M | $820.39K |
| Cash and equivalents | $758.62K | $457.74K | $42.22K | $27.56K | $28.76K |
| Total liabilities | $6.74M | $5.06M | $5.72M | $2.80M | $2.33M |
| Short-term debt | $494.16K | $690.97K | $1.62M | $203.41K | $664.15K |
| Long-term debt | $4.10M | $2.33M | N/A | N/A | N/A |
| Shareholder equity | $26.63M | -$1.05M | $15.60M | $563.11K | -$775.94K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $36.44M | $36.44M | $32.72M | $35.56M | N/A | $3.78M | N/A | $1.47M | $4.49M | $21.32M | $39.34M | $1.45M |
| Total liabilities | $10.72M | $10.72M | $6.74M | $6.82M | N/A | $5.06M | N/A | $8.55M | $1.24M | $5.72M | $4.43M | $1.50M |
| Cash and equivalents | $1.02M | $1.02M | $758.62K | $295.29K | N/A | $457.74K | N/A | $169.66K | $54.10K | $42.22K | $38.75K | $77.29K |
| Shareholder equity | $26.43M | $26.43M | $26.63M | $29.38M | N/A | -$844.61K | N/A | -$6.58M | $3.74M | $15.60M | $34.91M | $475.74K |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.93M | -$8.26M | -$857.36K | -$527.12K | $1.43M |
| Capital expenditures | $5.75M | $53.04K | $69.85K | $94.45K | $16.57K |
| Free cash flow | -$16.68M | -$8.32M | -$927.20K | -$621.58K | $1.42M |
| Investing cash flow | -$7.56M | -$53.05K | N/A | -$69.69M | -$16.57K |
| Financing cash flow | $18.99M | $8.68M | -$50.41M | $70.27M | -$1.54M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | N/A | N/A | -$6.35M | N/A | N/A | -$142.71K | -$142.71K | -$203.28K | -$34.67K |
| Capital expenditures | $0 | $0 | $2.82K | $0 | $0 | N/A | $0 | $0 | $1 |
| Free cash flow | N/A | N/A | -$6.36M | N/A | N/A | N/A | -$142.71K | -$203.28K | -$34.67K |
Frequently Asked Questions About NIVF
What is NewGenIvf Group Limited Class A Ordinary Shares' annual revenue?
NewGenIvf Group Limited Class A Ordinary Shares reported revenue of $4.73M for the fiscal year ended Dec 31, 2025.
How fast is NewGenIvf Group Limited Class A Ordinary Shares' revenue growing?
Revenue was down 13.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -7.4%.
Is NewGenIvf Group Limited Class A Ordinary Shares profitable?
Yes. NewGenIvf Group Limited Class A Ordinary Shares reported net income of $9.88M for the fiscal year ended Dec 31, 2025, with a net margin of 209.0%.
How much free cash flow does NIVF generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.93M minus capital expenditures of $5.75M produced free cash flow of -$16.68M.
How much debt does NewGenIvf Group Limited Class A Ordinary Shares have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $4.10M, short-term debt of $494.16K and cash and equivalents of $758.62K.
NIVF pages: Overview, Financials